Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals is a clinical-stage biotech developing RNAi-based therapeutics — plozasiran (ApoC-III mechanism for severe hypertriglyceridemia) is the near-term commercial catalyst, with FDA approval expected Q2 2027.

What the setup looks like:

• Fundamentals reflect the pre-commercial state — Q1 revenue fell 86% YoY to $73.7M (lumpy licensing basis) with 100% gross margin, and Q1 EPS beat consensus by 15%.
• The valuation is stretched but supported by pipeline economics — 17x TTM sales on a $12.2B cap with FY26 consensus revenue of $463M reflects the commercial-launch-year modeling; FY27 revenue estimate of only $327M implies lumpy licensing revenue continues to dominate.
• The Phase 3 SHASTA-3/4 data at ESC 2026 is the real anchor event — plozasiran lowered TG by ~80%, ApoC-III mechanism, proven acute pancreatitis reduction with NNT ~3 in prior-pancreatitis patients; this is landmark efficacy data.
• Zodasiran Phase 3 China data was also strong and safe — a real second pipeline validation.
• RBC reiterated Outperform with $100 PT (roughly 16% above spot), and Arrowhead is contrasted favorably vs IONS (4 injections/year vs 12).
• Insider selling is modest — director Perry sold $1M plus Olukotun $174K on 8/18; small trims relative to positions.
• Multiple September investor conferences upcoming — the specific window that typically produces re-rating on continued pipeline commentary.

Acceleration continues while pipeline data reads clean and FDA approval timing stays on track — Q1 fiscal 2027 earnings on Nov 24 with reaffirmed plozasiran launch preparation plus any partnership commentary extends this above $100; a Phase 3 safety signal or FDA delay stalls the tape. A break above $95 confirms the trend.